VA DV i lie r i st i ncd oxo ru h ic i ndcx amethas ojic

Self-assessment questions and answers are available at ht-tp://www.mhpharmacotherapy.com/pp.html.

references

1. Garcia-Manero G, Faderl S, O'Brien S, et al. Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer 2003;98:437-457.

2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.

3. Nowell PC. Progress with chronic myelogenous leukemia: A personal perspective over four decades. Annu Rev Med 2002;53:1-13.

4. Kantarjian H, Schiffer C, Jones D, et al. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCRABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods. Blood 2007;111:1774-1780.

5. Lowenberg B. Minimal residual disease in chronic myelogenous leukemia. NEngl J Med 2003;96:358-361.

6. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med 1999;131:207-219.

7. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Rockland, PA. Version 2009, www.nccn.org.

8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.

9. Druker BJ, Guilhot F, O'Brien S, et al. Five year follow-up of patients receiving imatinib for chronic myelogenous leukemia. N Eng J Med 2006;355:2408-2417.

10. Talpaz M, Silver TR, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002;99:1928-1937.

11. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetics responses in patients with chronic myeloid leukemia in myeloid blast crisis. Blood 2002;99:3530-3539.

12. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007;13:1089-1097.

13. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-923.

14. Deininger MWN, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.

15. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.

Wierda WG, Keating MJ, O'Brien S. Chronic Lymphocytic Leukemias. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia, PA: Lippincott, 2008:2278-2304.

Hallek M. Prognostic factors in chronic lymphocytic leukemia. Ann Oncol 2008;19:iv51-iv53.

Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program 2006:279-284.

Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.

Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998;338:1506-1514.

Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999;91:861-868.

Shanafelt TD, Kay NE. Comprehensive management of the CLL patient: A holistic approach. Hematology Am Soc Hematol Educ Program 2007:324-331.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non Hodgkin's Lymphoma. Rockland, PA. Version 3. 2008, www.nccn.org.

Wierda WG. Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program 2006:285-294.

Ferrajoli A, O'Brien SM. Treatment of chronic lymphocytic leukemia. Sem Oncol 2004;31:60-65.

Hillmen P. Advancing therapy for chronic lymphocytic leukemia—The role of rituximab. Sem Oncol 2004;31(Suppl 2):22-26.

Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.

Moreton P, Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Sem Oncol 2003;30:493-501.

Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088.

30. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078.

31. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-887.

32. Munshi NC, Anderson KC. Plasma cell neoplasms. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia, PA: Lippincott, 2008:2305-2342.

33. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873.

34. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.

35. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.

36. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Multiple Myeloma. Rockland, PA. Version 2. 2009, www.nccn.org.

37. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-19.

38. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomized trial. Lancet 2007;370:1209-1218.

39. Palumbo A, Rajkumar SV, Dimopoulous MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22(2):414-423.

40. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008:2962-2972.

41. Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.

42. Blade J, Cibeira MT, Rosinol L. Bortezomib: A valuable new antineoplastic strategy in multiple myeloma. Acta Oncologica 2005;44:440-448.

43. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zole-dronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.

44. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047-1053.

45. Kyle Ra, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2462-2472.

46. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:1564-1577.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment